4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-018694
CHIEF FINANCIAL OFFICER sold 4,250 shares at an average $22.57 ($95,922)
- CHIEF FINANCIAL OFFICER acquired 4,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-06-27 | Option exercise 10b5-1 | +4,250 | $2.48 | $10,540 | 4,250 | D: show line 1 in the form |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-06-27 | Sale 10b5-1 | −1,280 | $21.79 | $27,897 | 2,970 | D: show line 2 in the form |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-06-27 | Sale 10b5-1 | −1,830 | $22.58 | $41,313 | 1,140 | D: show line 3 in the form |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-06-27 | Sale 10b5-1 | −1,140 | $23.43 | $26,711 | 0 | D: show line 4 in the form |
| Open-market sales · 4,250 sh · avg $22.57 · $95,922 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2024-06-27 | Option exercise · Stock Option (right to buy) 10b5-1 | −4,250 | 212,620 | D: show line 5 in the form |
Loading xslF345X05/form4-07022024_120743.xml…